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Abstract
Background: Lung hyperinflation contributes to dyspnea, morbidity and mortality in chronic obstructive pulmonary
disease (COPD). The inspiratory-to-total lung capacity (IC/TLC) ratio is a measure of lung hyperinflation and is
associated with exercise intolerance. However, knowledge of its effect on longitudinal change in the 6-min walk
distance (6MWD) in patients with COPD is scarce. We aimed to study whether the IC/TLC ratio predicts longitudinal
change in 6MWD in patients with COPD.
Methods: This prospective cohort study included 389 patients aged 40–75 years with clinically stable COPD in
Global Initiative for Chronic Obstructive Lung Disease stages II-IV. The 6MWD was measured at baseline, and
after one and 3 years. We performed generalized estimating equation regression analyses to examine
predictors for longitudinal change in 6MWD. Predictors at baseline were: IC/TLC ratio, age, gender, pack years,
fat mass index (FMI), fat-free mass index (FFMI), number of exacerbations within 12 months prior to inclusion,
Charlson index for comorbidities, forced vital capacity (FVC), forced expiratory volume in 1 s (FEV1), and light
and hard self-reported physical activity.
Results: Reduced IC/TLC ratio (p < 0.001) was a statistically significant predictor for decline in 6MWD. With a
0.1-unit decrease in baseline IC/TLC ratio, the annual decline in 6MWD was 12.7 m (p < 0.001). Study
participants with an IC/TLC ratio in the upper quartiles maintained their 6MWD from baseline to year 3, while
it was significantly reduced for the patients with an IC/TLC ratio in the lower quartiles. Absence of light and
hard physical activity, increased age and FMI, decreased FEV1 and FVC, more frequent exacerbations and
higher Charlson comorbidity index were also predictors for lower 6MWD at any given time, but did not
predict higher rate of decline over the timespan of the study.
Conclusion: Our findings demonstrated that patients with less lung hyperinflation at baseline maintained their
functional exercise capacity during the follow-up period, and that it was significantly reduced for patients with increased
lung hyperinflation.
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Background
Chronic obstructive pulmonary disease (COPD) is a
major cause of morbidity and mortality, and is predicted
to become the third leading cause of death worldwide in
2030 [1]. Expiratory flow limitation is generally regarded
as the hallmark feature of COPD [2], but lung hyperin-
flation is also a manifestation of COPD with major clin-
ical consequences [3].
Lung hyperinflation is clinically relevant in COPD,
mostly because of its contribution to dyspnea [4] and
morbidity associated with the disease [5]. Hyperinflation
has also shown to be related to exercise limitation [4],
which is a significant component of quality of life [6].
The inspiratory capacity (IC) and inspiratory-to-total
lung capacity (IC/TLC) ratio are indirect measures of
lung hyperinflation reflecting the end-expiratory lung
volume [5, 7]. IC and IC/TLC ratio progressively
declines as COPD advances [7, 8], mirroring the rise in
lung hyperinflation [9].
The 6-min walk test (6MWT) is widely used in the
assessment of functional exercise capacity in patients
with COPD [10]. The 6-min walk distance (6MWD)
gives valuable information that can be used in the
clinical staging of COPD patients, as it correlates well
with dyspnea, lung hyperinflation and airway obstruction
[11]. In addition, longitudinal changes in 6MWD have
demonstrated to be important predictors of mortality
[12–14]. However, there is limited knowledge about the
effect of IC/TLC ratio on longitudinal changes in
6MWD in patients with COPD.
To our knowledge, only one previous study has exam-
ined the relationship between lung hyperinflation and
functional exercise capacity, using IC/TLC ratio and
6MWD in the assessment. Ramon et al. [15] demon-
strated that IC/TLC ratio and subjective dyspnea pre-
dicted decline in exercise capacity. However, Ramon
et al. [15] only included patients recruited during their
first hospitalization due to a COPD exacerbation, and
may not be representative for COPD patients in general.
The observation time was 1.7 years [15].
The aim of the present study was to examine whether
lung hyperinflation measured as IC/TLC ratio predicts
longitudinal change in 6MWD in patients with COPD.
We hypothesized that increased hyperinflation predicts




The current study was a prospective cohort study that
included 389 of a total of 433 patients from the Bergen
COPD Cohort Study (BCCS), aged 44–75 years, with an
average follow-up time of 3 years (2006–2010). Details of
sampling procedures and data collection for the BCCS have
been described previously [16]. In brief, all patients had a
clinically stable COPD in Global Initiative for Chronic
Obstructive Lung Disease (GOLD) stages II-IV [17], a
smoking history of ≥10 pack years, a post-bronchodilation
forced expiratory volume in 1 s (FEV1)/forced vital capacity
(FVC) ratio < 0.7 and a post-bronchodilation FEV1 < 80% of
predicted value according to Norwegian reference values
[18]. Exacerbations that required medical treatment and/or
hospitalization during the last 4 weeks prior to inclusion
led to postponement of inclusion. There were no restric-
tions to treatment during the study period, and the patients
received medications and therapies prescribed by their
physician. Active cancer or inflammatory disorders like
rheumatoid arthritis, systemic lupus erythematosus or other
connective tissue disorders and inflammatory bowel disease
in the last 5 years were reasons for exclusion from the
study. The patients were recruited through outpatient
clinics from several hospitals in Western Norway and from
three private specialist practices in Bergen, Norway [16].
Measurements
Six-min walk test
Functional exercise capacity was assessed by the 6MWT
with 6MWD as the primary outcome measure. The
6MWT was performed at baseline and after one and 3
years after inclusion in the study. The test was super-
vised by a trained technician and performed according
to the American Thoracic Society (ATS) guidelines [10].
However, the 6MWT was performed only once at each
visit without a prior practice test. The 6MWD and use
of oxygen during the test were registered. Measurements
of heart rate and oxygen saturation, as well as evaluation
of dyspnea and fatigue according to the Borg CR10 Scale
[19], were done before and immediately after the test.
Self-reported physical activity
Level of habitual physical activity was registered by a
questionnaire with two questions related to spare time
physical activity, one for hard and one for light physical
activity. Sweating and breathlessness were used as the
delineation between hard and light physical activity. The
possible response categories were none, less than 1 h per
week, 1–2 h per week and 3 or more hours per week.
These questions are validated previously [20, 21], and
have been used in a large Norwegian general population
study [22].
Body composition, spirometry, dyspnea, exacerbations and
Charlson index for comorbidities
We measured height and body mass, and the study
participants underwent bioelectrical impedance mea-
surements of fat mass and fat-free mass after an
overnight fast (Bodystat 1500, Isle of man, England).
Fat mass index (FMI) and fat-free mass index (FFMI)
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were calculated as fat mass and fat-free mass,
respectively, divided by the square of height.
The study participants underwent complete lung func-
tion tests at baseline, including spirometry and plethys-
mography, according to the ATS/ERS Standardization of
Lung Function Testing [23, 24]. We performed spirometry
before and after inhalation of 0.4 mg salbutamol on a
Viasys Masterscope (Viasys, Hoechberg, Germany). The
FVC and FEV1 were taken as the highest values from at
least three acceptable and repeatable maneuvers. Lung
volumes were obtained by plethysmography and lung
hyperinflation was assessed by the IC/TLC ratio. The
spirometers were calibrated twice daily with a 3-L calibra-
tion syringe.
The modified Medical Research Council (mMRC)
dyspnea scale [25] was used to measure symptoms of
dyspnea. A physician examined all the patients at
baseline and registered number of exacerbations the
last 12 months prior to inclusion, comorbidities and
smoking habits. The Charlson index for comorbidities
was calculated.
Statistics
Descriptive statistics were used to characterize the
study population (mean, standard deviation and per-
cent). Normal distribution was assessed by histogram,
Q-Q-plot and Shapiro Wilks test. We compared the
continuous and categorical variables across gender by
independent t-tests and chi-square tests, respectively.
We performed generalized estimating equations
(GEE) regression analyses [26] to examine IC/TLC
ratio as predictor for change in 6MWD. Time was
included in the model as a categorical variable with
three measurements: baseline, 1 and 3 years, and in
addition as a continuous variable to examine yearly
change in 6MWD. Age, gender, pack years, FMI,
FFMI, more than two exacerbations within 12months
prior to inclusion (yes/no), Charlson index for comorbid-
ity (level 1, 2, 3 and 4), FVC, FEV1 and light or hard
self-reported physical activity (yes/no, yes = ≥1 h/week) at
baseline were included as potential confounders. To
account for within-patient correlation we applied an
unstructured working correlation structure. GEE regres-
sion analysis provides an approach for analyzing corre-
lated measurements without excluding subjects with an
incomplete dataset.
We performed bivariate GEE analysis for each predictor
variable. In an additional analysis, time was investigated as
a continuous variable. Multivariate GEE analyses were
performed in three stages, first including all variables as
main effects, and secondly, expanding with all possible
interaction terms between predictor and time. Based on the
latter, the third and final model included all variables and
the statistically significant interaction terms. Analyses for
multicollinearity between FMI and FFMI, and between IC/
TLC ratio, FVC and FEV1 did not demonstrate multicolli-
nearity, and therefore all variables were included in the
same model.
In addition, we performed multivariate GEE analyses
with baseline IC/TLC ratio categorized into quartiles, and
the variable was included in the analysis as the interaction
term with time. The IC/TLC groups were named IC/TLC
1, 2, 3 and 4, respectively, with IC/TLC 1 representing the
lower quartile.
A power analysis for a simple group comparison with
three repeated measures [26] informed that 174 patients
were needed to detect a difference in mean 6MWD of 30m
[27] as statistically significant at a 5% significance level and
a power of 80%. The calculation was based on an assump-
tion of a within-subject correlation coefficient of 0.25 and a
SD for 6MWD of 100m. A within-subject correlation
coefficient of 0.5 increased the number of patients to 232.
IBM SPSS Statistics version 24 was used to conduct
the analyses. Estimated regression coefficients obtained
in the GEE analyses are presented with confidence




At baseline, 389 patients completed the 6MWT, and 319
(82%) and 264 (68%) completed the 6MWT at 1 year and
3-years, respectively. Of the remaining 125 participants, 104
were disabled and 21 were deceased. The patients who
dropped out were older (p < 0.001), had lower FEV1 (p
< 0.001), FVC (p < 0.001) and IC/TLC ratio (p < 0.001)
compared to the patients who completed the study, and
the 6MWD were 87 m (p < 0.001) shorter at baseline.
Baseline characteristics of the study population are
presented in Table 1. The mean age of the patients was
64 ± 7 years, and 61% were male. Airflow limitation was
moderate to very severe with a mean FEV1 of 49 ± 14%
of predicted value. Measurements of IC/TLC ratio at
baseline were available for 371 patients. The patients
had a mean IC/TLC ratio of 0.35 ± 0.09 and approxi-
mately 15% of the patients had an IC/TLC ratio below
the critical threshold of 0.25. The cut points for the
quartiles were 0.29 (25th percentile), 0.34 (median) and
0.40 (75th percentile).
Longitudinal change in 6MWD
Estimated unadjusted mean (SE) 6MWD at baseline and
after 1 and 3 years were 429 (6), 437 (6) and 408 (8) m,
respectively. There was a statistically significant annual
decrease in 6MWD during the follow-up period of − 10.9
m (95% CI: -15.3 – -6.6, p < 0.001). However, mean 6MWD
increased slightly from baseline to year 1 (B = 8.1, p = 0.05)
(Table 2), and was significantly reduced from year 1 to year
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3 (B = − 29, p < 0.001) indicating a non-linear relationship.
This pattern was most evident in patients with an IC/TLC
ratio in the lower quartiles (Fig. 1).
Predictors for longitudinal change in 6MWD
A 0.1 unit increase in baseline IC/TLC ratio was
associated with an increase in 6MWD both in the
Table 1 Baseline characteristics of the study population
Predictors Total Female Male P-value
Sex, n (%) 389 (100) 153 (39.3) 236 (60.7)
Age (years) 63.6 ± 6.8 62.6 ± 6.3 64.2 ± 7.0 0.028
6MWD (m) 423 ± 112 406 ± 104 434 ± 115 0.015
SpO2 before 6MWT (%) 94.2 ± 2.7 94.1 ± 2.9 94.3 ± 2.6 0.621
SpO2 after 6MWT (%) 91.0 ± 5.7 90.9 ± 6.1 91.0 ± 5.4 0.804
Borg dyspnea score after 6MWT (median) 4.0 4.0 3.0 0.085
mMRC 2.2 ± 2.3 2.3 ± 2.4 2.1 ± 2.2 0.410
BMI (kg/m2) 25.4 ± 5.2 24.5 ± 5.7 25.9 ± 4.8 0.016
FMI (kg/m2) 8.4 ± 3.3 9.8 ± 3.7 7.4 ± 2.6 < 0.001
FFMI (kg/m2) 17.0 ± 3.2 14.7 ± 2.4 18.5 ± 2.8 < 0.001
Smoking status n (%) 0.215
Current 167 (43) 72 (47) 95 (40)
Former 222 (57) 81 (53) 141 (60)
Pack years 40.9 ± 22.8 33.5 ± 16.6 45.6 ± 24.9 < 0.001
GOLD category, n % 0.283
II 179 (46) 76 (50) 103 (44)
III 169 (43) 65 (42) 104 (44)
IV 41 (11) 12 (8) 29 (12)
Charlson comorbidity index, n (%) 0.011
1 225 (58) 99 (65) 126 (53)
2 93 (24) 38 (25) 55 (23)
3 46 (12) 12 (8) 34 (15)
4 25 (6) 4 (2) 21 (9)
Experienced > 2 exacerbations, n (%) 75 (20) 38 (25) 37 (16) 0.036
FEV1 (L) 1.5 ± 0.5 1.3 ± 0.4 1.7 ± 0.5 < 0.001
FEV1 (% pred.) 48.7 ± 14.0 49.6 ± 13.5 48.1 ± 14.4 0.315
FVC (L) 3.3 ± 0.9 2.7 ± 0.6 3.7 ± 0.8 < 0.001
FVC (% pred.) 85.5 ± 16.6 85.2 ± 17.1 85.6 ± 16.4 0.791
FEV1/FVC (%) 45.7 ± 11.1 47.6 ± 11.0 44.5 ± 11.0 0.006
TLC (L) 7.1 ± 1.4 6.1 ± 0.9 7.8 ± 1.3 < 0.001
TLC (% pred.) 115.9 ± 18.0 121.4 ± 17.8 112.3 ± 17.1 < 0.001
IC (L) 2.4 ± 0.7 2.0 ± 0.5 2.7 ± 0.7 < 0.001
IC/TLC ratio 0.35 ± 0.09 0.36 ± 0.08 0.33 ± 0.09 0.002
TLCO 5.2 ± 1.9 4.4 ± 1.6 5.6 ± 2.0 < 0.001
TLCO (% pred.) 59.1 ± 18.8 57.2 ± 18.5 60.3 ± 19.0 0.143
Physical activity ≥1 h/week
Light physical activity 263 (73.0) 104 (73.7) 159 (72.6) 0.691
Hard physical activity 141 (39.6) 54 (38.9) 88 (40.6) 0.139
Data are presented as mean ± SD, unless otherwise stated. Independent samples T-test for continuous variables and Chi square for
categorical variables
6MWD 6-min walking distance, BMI body mass index, FMI fat mass index, FFMI fat free mass index, GOLD Global Initiative for Chronic Obstructive
Lung Disease, FEV1 forced expiratory volume in 1 s, FVC forced vital capacity, IC inspiratory capacity, TLC total lung capacity, IC/TLC ratio inspiratory-
to-total lung capacity ratio, TLCO transfer factor for carbon monoxide
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bivariate (B = 489m, p < 0.001) and multivariate (B = 229m,
p = 0.001) analysis (Table 2). In the final model, we allowed
for a time-dependent effect of the IC/TLC ratio, and found
that it gained importance as predictor of 6MWD with
longer follow-up (Table 2). Among all included factors, only
IC/TLC ratio demonstrated a statistically significant
time-dependent effect on 6MWD (p < 0.001). However,
several other baseline factors had a statistically significant
impact on 6MWD irrespective of follow-up. We observed
that not performing light and hard physical activity,
decreasing values of FEV1 or FVC, increasing age or FMI,
Charlson comorbidity index of 3 or higher, and having
more than two exacerbations the last 12months prior to
study inclusion, predicted a statistically significant decrease
in 6MWD (Table 2).
Discussion
The main findings of this study were: 1) Increased
lung hyperinflation measured as IC/TLC ratio pre-
dicted longitudinal decline in 6MWD, with time as an
effect modifier. Absence of light and hard physical
activity, increased age and FMI, decreased FEV1 and
FVC, more frequent exacerbations and higher Charl-
son comorbidity index were also predictors for lower
6MWD at any given time, but did not predict higher
rate of decline over the timespan of the study. 2)
Study participants with an IC/TLC ratio in the upper
quartiles maintained their 6MWD from baseline to
year 3, while it was significantly reduced for study
participants with an IC/TLC ratio in the lower
quartiles.
Longitudinal change in 6MWD
The analysis of data with repeated outcome measure-
ments over time is complicated. Baseline predictor
variables can be associated to the outcome at any given
time point without actually predicting the time-related
change in the outcome. It is the interaction of time and
the baseline variable (effect modification) which shows
whether there is a prediction of change in the outcome
over time. In our study, only IC/TLC ratio interacted
significantly with time, and as such, was the only
variable to actually predict a change in the 6MWD.
Table 2 Predictors for mean 6MWD estimated with GEE regression analysis
Predictors Bivariate Multivariatea
Beta p Beta 95% CI p
Time < 0.001 < 0.001b
1 year vs. baseline 8.1 0.052 6.0 - 1.9 – 13.4 0.134
3 years vs. baseline - 21.0 < 0.001 - 24.1 - 35.1 – - 13.9 < 0.001
Sex, (male vs. female) 35.1 0.002 - 28.8 - 60.1 – 2.5 0.072
Age (years) - 5.3 < 0.001 - 1.8 - 3.4 – - 0.3 0.019
FEV1 (L) 107.3 < 0.001 47.5 21.7–73.2 < 0.001
FVC (L) 57.1 < 0.001 20.9 5.2–36.7 0.009
IC/TLC ratio (at 0.35) 489.4 < 0.001 < 0.001c
At baseline 116.3 −10.0 – 242.7 0.071
At 1 year 175.2 25.1–325.4 0.022
At 3 years 454.2 263.3–645.2 < 0.001
FMI (kg/m2) - 8.2 < 0.001 - 8.3 - 12.2 – - 4.4 < 0.001
FFMI (kg/m2) 5.2 0.008 1.3 - 3.6 – 6.3 0.592
Pack years - 0.2 0.577 - 0.2 - 0.7 – 0.3 0.421
Experienced > 2 exacerbations last year - 66.4 < 0.001 - 32.1 - 53.5 – - 10.7 0.003
Charlson comorbidity index; score 0.001 0.006b
2 vs. 1 - 30.6 0.025 - 12.1 - 33.5 – 9.2 0.266
3 vs. 1 - 56.6 0.003 - 37.4 - 68.7 – - 6.1 0.019
4 vs. 1 - 58.9 0.016 - 54.8 - 91.6 – - 18.0 0.004
Light physical activity ≥1 h/week 69.9 < 0.001 34.2 7.5–60.8 0.012
Hard physical activity ≥1 h/week 66.4 < 0.001 37.0 18.6–55.4 < 0.001
Beta estimated regression coefficient, P p-value, CI confidence interval, 6MWD 6-min walk distance, GEE generalized estimated equation, FEV1 forced expiratory
volume in one second, FVC forced vital capacity, IC/TLC ratio inspiratory-to-total lung capacity ratio, FMI fat mass index, FFMI fat free mass index
a The model included all predictors and interaction terms for time x IC/TLC ratio centered at mean value (0.35). b Test for overall effect. c Test for time as effect
modifier (test of interaction)
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To our knowledge, only four previous studies have
investigated risk factors for decline in functional exercise
capacity assessed by the 6MWT in patients with COPD
[12, 15, 28, 29]. Of these, only one study has examined
the relationship between lung hyperinflation and func-
tional exercise capacity. Ramon et al. [15] conducted a
prospective cohort study with 342 patients with a clinic-
ally stable COPD, and a mean follow-up period of 1.7
years. The study demonstrated that IC/TLC ratio and
dyspnea score predicted decline in functional exercise
capacity measured by 6MWD.
We confirmed the findings from Ramon et al. by dem-
onstrating that IC/TLC ratio predicted longitudinal
change in functional exercise capacity. However, patients
in the study by Ramon et al. [15] were recruited during
their first hospitalization due to a COPD exacerbation,
and performed two 6MWTs, the first at least 3 months
after discharge from hospital and the second 18–24
months after the first test. The period of follow-up was
relatively short. Our study included a wide spectrum
of patients with clinically stable COPD in GOLD
stages II-IV that performed the 6MWT three times
during a follow-up period of 3 years. We also demon-
strated, irrespective of follow-up, associations between
a decrease in 6MWD and a decrease in FEV1 and
FVC, increased age, FMI, comorbidity and number of
exacerbations and absence of light and hard physical
activity.
Previous studies have demonstrated that airflow limi-
tation (lower FEV1) and older age were risk factors for
longitudinal decline in functional exercise capacity [12,
28, 29]. In addition, Spruit et al. [29] found that lower
body mass index (BMI) was a predictor for longitudinal
change in functional exercise capacity. Our group has
previously demonstrated in the same cohort as in this
study, that lower levels of habitual hard physical activity
is associated with an increased deterioration in func-
tional exercise capacity [28]. In consistency with previ-
ous research [12, 28, 29], we demonstrated in this study
that lower FEV1 and older age were associated with a
lower 6MWD. A lower FEV1 is related to reduced max-
imal expiratory flow rates and impaired ventilatory
capacity, being a limiting factor for functional exercise
capacity.
Lung hyperinflation predisposes for a mechanical
constraint on expansion of the tidal volume as the need
for ventilation increases during exercise, resulting in
exercise intolerance [9, 30]. Performing light and hard
habitual physical activity demonstrated a positive associ-
ation with 6MWD. However, these results were not
significant when analyzing for time as an effect modifier.
Physical activity improves exercise capacity and the
function of the skeletal and muscle system, but it does
not improve the bronchial obstruction in patients with
COPD [31].
We did not examine whether BMI was a predictor for
change in 6MWD, but included FMI in the analysis,
which was a statistically significant predictor at 1 and 3
years. A novel finding from our study is that a higher
frequency of COPD exacerbations and a higher Charlson
Fig. 1 Estimated mean 6-min walk distance (6MWD) by quartiles of inspiratory-to-total lung capacity (IC/TLC) ratio at baseline and during 3 years
of follow-up. IC/TLC ratio at baseline was divided into approximate quartiles. IC/TLC ratio and the interaction term with time was included in an
unadjusted generalized estimating equations regression analyses
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comorbidity index were predictors for a lower 6MWD.
As previously demonstrated by Park et al. [8], progres-
sion of lung hyperinflation is associated with more
frequent exacerbations.
Studies have demonstrated that IC/TLC ratio declines
over time in patients with COPD [7, 32], including a re-
cent study conducted by Park et al. [8] that demon-
strated a decline in IC/TLC ratio over time at a mean
rate of 0.70% per year. As such, one expects that the
patients experience a progression of lung hyperinflation
during the study period, associated with a decline in
IC/TLC ratio [8]. Patients in the lower quartiles of IC/
TLC ratio experienced a higher decrease in 6MWD
during the follow-up period compared to participants
with an IC/TLC ratio in the higher quartiles, who
maintained their 6MWD.
Different variables show up as significant predictors
in different studies. Whether it is FEV1 or IC/TLC
ratio, or markers of clinical severity or body compos-
ition, they all reflect status of the lung mechanics and
clinical condition, which are the two most important
factors describing the severity of the disease.
Functional exercise capacity
Functional exercise capacity is determined by central
and peripheral factors, and the mechanism is complex
[33]. In patients with COPD, exercise capacity is
mainly limited by peripheral muscle fatigue, impaired
ventilatory mechanics and gas exchange [33, 34].
With an increased lung hyperinflation, the patients
experiences increased work of breathing. The respira-
tory muscles are placed at mechanical disadvantage
due to adaptation of the diaphragm to chronic over-
load of the respiratory muscles [28, 35, 36]. This
results in impaired inspiratory muscle strength [37]
and endurance [38], leading to dyspnea [39, 40] and
reduced exercise capacity [41]. Breathing becomes
more energy demanding and physical activity becomes
increasingly uncomfortable, resulting in a decreased
level of habitual physical activity, and secondly, a
deterioration in functional exercise capacity.
Our results demonstrates that performing habitual
physical activity at baseline was associated with 6MWD
in a positive manner.
Lung hyperinflation
IC can be measured by spirometry, and lung hyperin-
flation is therefore an easy way to evaluate the
patient’s disease severity and risk for functional exer-
cise capacity deterioration. Recent studies have dem-
onstrated that IC can be within the normal range in
patients with mild airway obstruction in GOLD stage
I, although residual volume (RV) and functional
residual capacity (FRC) can be increased [8, 42],
pointing towards early hyperinflation. To be able to
detect early hyperinflation, we chose to analyze IC/
TLC ratio, instead of IC alone. We could also have
used the RV/TLC ratio as an explanatory variable,
which is another widely used index for lung hyperin-
flation. In order to compare our findings with those
of Ramon et al. [15], we chose to use IC/TLC ratio.
We performed additional analyses with RV/TLC
instead of IC/TLC ratio, yielding approximately the
same results.
Study strengths and limitations
The current study was a large cohort consisting of
patients with clinically stable COPD in GOLD stages
II-IV. The large sample size, wide spectrum of disease
severity and quite even distribution among gender are
clear strengths of our study. This prospective study is
also one of few to consider the relationship between
longitudinal change in 6MWD and IC/TLC ratio.
The 6MWT with 6MWD as main outcome is a widely
used measure of functional exercise capacity in COPD,
but the cardiopulmonary exercise test (CPET) performed
on cycle ergometer or treadmill, is considered as the
gold standard for evaluating causes of exercise intoler-
ance in patients with COPD [43]. Peak oxygen uptake
(VO2peak) is the main outcome of CPET. The association
between 6MWD and VO2peak has shown to be moderate
to strong [44, 45] and the 6MWD a reliable measure of
walking capacity [46, 47].
In healthy persons and patients with mild COPD,
the 6MWT often shows a ceiling effect where it is
the maximal walking speed rather than the ventilatory
capacity that limits the 6MWD [28]. For some of our
patients, the 6MWD was not different from the
normal population. A longitudinal decline in 6MWD
has been demonstrated in previous studies [12, 29],
but this finding was only evident in patients with
severe airflow obstruction. Even though there was a
decline in 6MWD for patients in GOLD stages III
and IV, the mean annual decline was less than 30 m
that is considered the minimal clinically significant
change [27].
The patients were evaluated three times during the
follow-up period of 3 years, performing one 6MWT
at each visit. Since the test-battery in the BCCS was
comprehensive and demanding for the patients, only
one 6MWT was performed at each visit rather than
two, which is recommended by the ATS guidelines.
By doing two tests, any learning effect is reduced. A
decline in 6MWD could therefore have been
concealed by the learning effect, and could explain
our finding of no change in 6MWD after 1 year.
However, it is more unlikely that this effect influ-
enced the results after 3 years.
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This study was a subsample of the BCCS, in which
patients with inflammatory diseases were excluded.
However, patients with chronic diseases like heart fail-
ure were included in the study. A possible limitation of
our study is the possible effect that such comorbid
disease could influence longitudinal change in 6MWD.
Regardless, our findings are likely generalizable because
comorbid diseases are common among patients with
COPD and our study population is assumedly representa-
tive for common COPD patients. This is also accounted
for by including Charlson comorbidity index in the
analyses.
Patients were free to receive medication and therapy,
such as pulmonary rehabilitation, during the study. This
may have influenced the longitudinal change in 6MWD.
Frisk et al. [28] reported that patients participating in a
pulmonary rehabilitation program during the study
period reported a higher level of habitual physical activ-
ity at 3 years follow-up. However, hard physical activity
and FEV1 remained as significant predictors for change
in 6MWD when separate analyses were done for patients
who did participate in pulmonary rehabilitation and
those who did not [28].
Our study had a dropout rate of 32% from baseline to
year 3. Most patients were lost to follow-up because of
increased disease severity or death. Our dropout rate is
comparable to the dropout rate of 31% in the study by
Spruit et al. [29], which also had a study period of 3
years. The study by Casanova et al. [12] had a dropout
rate of 34% during a study period of 5 years. In studies
with COPD patients, an increasing dropout rate is hard
to avoid due to progression of the disease during longi-
tudinal studies.
Conclusion
Baseline IC/TLC ratio was a statistically significant
predictor for longitudinal change in 6MWD over a
period of 3 years. Patients with less lung hyperinfla-
tion at baseline maintained their functional exercise
capacity in the follow-up period, while it declined
significantly in those with increased hyperinflation.
Clinical implications
Decline in functional exercise capacity can to a certain
degree be prevented by therapeutic interventions such
as pulmonary rehabilitation [48]. It is useful to be able
to identify patients that are at particular risk for such
deterioration, in order to modify the course of disease.
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